Western Wealth Management LLC Grows Stake in Danaher Co. (NYSE:DHR)

Western Wealth Management LLC grew its stake in Danaher Co. (NYSE:DHR) by 5.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,206 shares of the conglomerate’s stock after purchasing an additional 338 shares during the quarter. Western Wealth Management LLC’s holdings in Danaher were worth $1,551,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the period. Wellington Management Group LLP grew its stake in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after buying an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares in the last quarter. Capital International Investors raised its stake in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares during the last quarter. Finally, Norges Bank bought a new stake in Danaher in the fourth quarter worth $1,752,382,000. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold 38,707 shares of company stock valued at $10,786,944 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of DHR stock traded up $1.94 during mid-day trading on Monday, hitting $271.26. The company had a trading volume of 237,260 shares, compared to its average volume of 2,846,200. The company has a market capitalization of $200.92 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.62 and a beta of 0.83. The stock’s 50 day moving average price is $257.69 and its 200-day moving average price is $253.60. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. SVB Leerink increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Citigroup increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Evercore ISI cut their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada increased their price objective on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Bank of America upped their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.